Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 8/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | STAMBP | O95630 | 1/20 | 0.36 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28106132 | 0.98 | NNMT (0.46) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL30255493 | 0.79 | NNMT (0.47) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL35211576 | 0.73 | NNMT (0.45) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL17675123 | 0.70 | NNMT (0.49) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL16495711 | 0.69 | NNMT (0.56) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL30370430 | 0.69 | NNMT (0.48) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL26607684 | 0.67 | NNMT (0.58) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL17675163 | 0.67 | NNMT (0.58) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL6282473 | 0.66 | NNMT (0.51) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL31239059 | 0.66 | NNMT (0.51) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025097247-A1 | METHOD OF TREATMENT OF FIBROSIS WITH INVERSE AGONIST OF RAR RELATED ORPHAN RECEPTORS (RORS) | 11949098 CANADA INC. (CA) | 2025-05-15 | — | — | WO | claimed |
| WO-2025097247-A1 | METHOD OF TREATMENT OF FIBROSIS WITH INVERSE AGONIST OF RAR RELATED ORPHAN RECEPTORS (RORS) | 11949098 CANADA INC. (CA) | 2025-05-15 | — | — | WO | disclosed |